Volume 28, Number 3—March 2022
Dispatch
Long-Term Symptoms among COVID-19 Survivors in Prospective Cohort Study, Brazil
Lívia P. Bonifácio, Viviane N.F. Csizmar, Francisco Barbosa-Júnior, Ana P.S. Pereira, Marcel Koenigkam-Santos, Danilo T. Wada, Gilberto G. Gaspar, Felipe S. Carvalho, Valdes R. Bollela, Rodrigo C. Santana, João P. Souza, and Fernando Bellissimo-Rodrigues
Table 2
Comparison of long-term symptom occurrence among COVID-19 survivors according to disease severity, Ribeirão Preto, Brazil*
| Long-term symptoms | COVID-19 severity |
Total, n = 175 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mild/moderate vs. severe |
Mild/moderate vs. critical |
|||||||||
| Mild/moderate, n = 35 | Severe, n = 80 | OR (95% CI) | p value† | Mild/moderate, n = 35 | Critical, n = 60 | OR (95% CI) | p value† | |||
| Mean time from onset of symptoms to inclusion, d (SD) | 51 (+27) | 48 (+23) | 51 (+27) | 72 (+26) | 57 (+27) | |||||
| Median |
43 |
41 |
43 |
74.5 |
50 |
|||||
| Need for readmission |
0 |
1 (1.3) |
– |
1.000 |
0 |
1 (1.7) |
– |
1.000 |
2 (1.1) |
|
| Persistent symptoms | ||||||||||
| No | 10 (28.6) | 21 (26.3) | 10 (28.6) | 4 (6.7) | 35 (20) | |||||
| Yes |
25 (71.4) |
59 (73.8) |
1.12 (0.46–2.73) |
0.822 |
25 (71.4) |
56 (93.3) |
5.60 (1.60–19.58) |
0.006‡ |
140 (80) |
|
| Respiratory symptoms | n = 25 | n = 59 | 25 | n = 56 | 140 | |||||
| Dyspnea | 9 (36) | 22 (37) | 1.06 (0.40–2.80) | 1.000 | 9 (36) | 15 (27) | 0.65 (0.24–1.78) | 0.437 | 46 (32) | |
| Cough | 4 (16) | 20 (34) | 2.69 (0.81–8.92) | 0.118 | 4 (16) | 16 (29) | 2.10 (0.62–7.09) | 0.275 | 40 (29) | |
| Rhinorrhea |
0 |
4 (7) |
– |
0.313 |
0 |
3 (5) |
– |
0.549 |
7 (5) |
|
| MRC Dyspnea Scale | n = 9 | n = 22 | n = 9 | n = 15 | 46 | |||||
| Level 1–2 | 6 (67) | 14 (64) | 0.88 (0.17–4.49) | 1.000 | 6 (67) | 6 (40) | 0.33 (0.06–1.88) | 0.615 | 26 (56) | |
| Level 3–5 |
3 (33) |
8 (36) |
0.29 (0.06–1.47) |
3 (33) |
9 (60) |
3.00 (0.53–16.9) |
0.412 |
20 (44) |
||
| Cardiovascular symptoms | n = 25 | n = 59 | n = 25 | n = 56 | 140 | |||||
| Swelling | 2 (8) | 6 (67) | 1.03 (0.16–6.62) | 1.000 | 2 (8) | 5 (9) | 1.13 (0.20–6.25) | 1.000 | 13 (9) | |
| Hypertension | 1 (4) | 0 | – | 0.298 | 1 (4) | 1 (2) | 0.44 (0.03–7.27) | 0.525 | 2 (1) | |
| Hypotension |
0 |
1 (2) |
– |
1.000 |
0 |
1 (2) |
– |
1.000 |
2 (1) |
|
| Neurologic symptoms | n = 25 | n = 59 | n = 25 | n = 56 | 140 | |||||
| Headache | 10 (40) | 16 (27) | 0.56 (0.21–1.49) | 0.304 | 10 (40) | 10 (18) | 0.33 (0.11–0.93) | 0.050‡ | 36 (26) | |
| Altered skin sensitivity | 1 (4) | 4 (7) | 1.75 (0.19–16.45) | 1.000 | 1 (4) | 21 (38) | 14.4 (1.8–114.3) | 0.001‡ | 26 (19) | |
| Hypogeusia | 6 (24) | 10 (17) | 0.65 (0.21–2.03) | 0.545 | 6 (24) | 3 (5) | 0.18 (0.04–0.79) | 0.022‡ | 19 (14) | |
| Hyposmia | 7 (28) | 7 (12) | 0.35 (0.11–1.12) | 0.107 | 7 (28) | 4 (7) | 0.20 (0.05–0.76) | 0.030‡ | 18 (13) | |
| Dysgeusia | 3 (12) | 3 (5) | 0.39 (0.07–2.10) | 0.356 | 3 (12) | 7 (13) | 1.05 (0.25–4.44) | 1.000 | 13 (9) | |
| Loss of recent memory (brain fog) |
2 (8) |
3 (5) |
0.62 (0.10–3.93) |
0.631 |
2 (8) |
3 (5) |
0.65 (0.10–4.16) |
0.642 |
8 (6) |
|
| Gastrointestinal symptoms | n = 25 | n = 59 | n = 25 | n = 56 | 140 | |||||
| Diarrhea | 0 | 2 (3) | – | 1.000 | 0 | 4 (7) | – | 0.306 | 6 (4) | |
| Stomach pain |
2 (8) |
0 |
– |
0.086 |
2 (8) |
0 |
– |
0.093 |
2 (1) |
|
| Other symptoms, n | n = 25 | n = 59 | n = 25 | n = 56 | 140 | |||||
| Fatigue | 10 (40) | 23 (39) | 0.96 (0.37–2.49) | 1.000 | 10 (40) | 22 (39) | 0.97 (0.37–2.54) | 1.000 | 54 (39) | |
| Muscle weakness | 3 (12) | 11 (19) | 1.68 (0.43–6.63) | 0.539 | 3 (12) | 21 (38) | 4.4 (1.17–16.5) | 0.033‡ | 35 (25) | |
| Vision impairment | 1 (4) | 1 (2) | 0.41 (0.03–6.89) | 0.509 | 1 (4) | 8 (14) | 4 (0.47–33.86) | 0.262 | 10 (7) | |
| Loss of hair | 2 (8) | 3 (5) | 0.62 (0.10–3.93) | 0.631 | 2 (8) | 4 (7) | 0.89 (0.15–5.18) | 1.000 | 9 (6) | |
*Values are no. (%) except as indicated. –, calculation could not be performed. †p values were calculated using Fisher exact test. ‡p<0.05.
Page created: December 27, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.